Question 1

What is AXS-12?

Accepted Answer

AXS-12 is a Other.

Question 2

How often does AXS-12 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 9 articles.

Question 3

When was AXS-12 first tracked by Ergen?

Accepted Answer

First tracked on Jul 15, 2026.

Question 4

When was AXS-12 last mentioned in news?

Accepted Answer

Last active on Jul 15, 2026.

Question 5

What is AXS-12's current news sentiment?

Accepted Answer

Aggregate sentiment score: 15 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AXS-12 in global news coverage?

Accepted Answer

Attention score of 3, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AXS-12?

Accepted Answer

FDA accepts Axsome NDA for AXS-12 (Jul 15, 2026, 9 articles).

Question 8

How did the "FDA accepts Axsome NDA for AXS-12" event impact AXS-12?

Accepted Answer

AXS-12 is the drug candidate under review; FDA acceptance advances its path to potential approval for cataplexy in narcolepsy.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.